| Mark A Morisaki Md Inc | |
|
98-1079 Moanalua Rd Ste 620 Aiea HI 96701-4716 | |
| (808) 488-2224 | |
| Not Available |
| Full Name | Mark A Morisaki Md Inc |
|---|---|
| Speciality | Internal Medicine |
| Location | 98-1079 Moanalua Rd Ste 620, Aiea, Hawaii |
| Authorized Official Name and Position | Mark A Morisaki (OWNER) |
| Authorized Official Contact | 8084882224 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mark A Morisaki Md Inc Po Box 25370 Honolulu HI 96825-0370 Ph: (808) 536-0314 | Mark A Morisaki Md Inc 98-1079 Moanalua Rd Ste 620 Aiea HI 96701-4716 Ph: (808) 488-2224 |
| NPI Number | 1114042868 |
|---|---|
| Provider Enumeration Date | 03/20/2007 |
| Last Update Date | 10/23/2007 |
| Medicare PECOS PAC ID | 7113023680 |
|---|---|
| Medicare Enrollment ID | O20070430000116 |
News Archive
The report offers comprehensive up-to-date information on injury incidence, including transport accidents, intentional self-harm and suicide, assault and accidental poisoning, hospitalisations and deaths among young people in Australia.
University of Rochester researchers believe they're on track to solve the mystery of weight gain - and it has nothing to do with indulging in holiday eggnog.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114042868 | NPI | - | NPPES |
| 526907 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 11904 (Hawaii) | Primary |
| Provider Name | Mark A Morisaki |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1861441909 PECOS PAC ID: 9537265012 Enrollment ID: I20070430000157 |
News Archive
The report offers comprehensive up-to-date information on injury incidence, including transport accidents, intentional self-harm and suicide, assault and accidental poisoning, hospitalisations and deaths among young people in Australia.
University of Rochester researchers believe they're on track to solve the mystery of weight gain - and it has nothing to do with indulging in holiday eggnog.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.
› Verified 6 days ago
News Archive
The report offers comprehensive up-to-date information on injury incidence, including transport accidents, intentional self-harm and suicide, assault and accidental poisoning, hospitalisations and deaths among young people in Australia.
University of Rochester researchers believe they're on track to solve the mystery of weight gain - and it has nothing to do with indulging in holiday eggnog.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.
› Verified 6 days ago
Rice Consultancy Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi St, Suite 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 | |
Ky Le Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1079 Moanalua Rd, Aiea, HI 96701 Phone: 808-536-0300 | |
Yousif A-rahim Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi St, 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 | |
Luis J. Ragunton, M.d., Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1079 Moanalua Rd, Suite 440, Aiea, HI 96701 Phone: 808-488-8750 Fax: 808-487-5910 | |
Randall J. Nitta, Md, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1247 Kaahumanu St Ste 306, Aiea, HI 96701 Phone: 808-484-2904 Fax: 808-484-2864 | |
Robert Wong, Md, L.l.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi Street, Suite 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 |